INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
The company's breast cancer screen test has also demonstrated superior accuracy over current tests.
Copyright 2024 – Finance News Network
Source: Finance News Network
14 Dec 2021 - icetana Limited (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses the company's $2.7m share placement, as well as recent deals with NEC and Panasonic.
Read More10 Jul 2023 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent news, including excellent sensitivity and specificity results for the company's SubB2M breast cancer test.
Read More10 Jan 2020 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, discusses funding for the Novatti's banking subsidiary, its banking licences and its core customer acquisition proposition.
Read More05 Sep 2019 - Mitchell Services Limited (ASX:MSV) CEO, Andrew Elf talks FY19 results, improved trading conditions and strategy.
Read More20 May 2021 - Complii FinTech Solutions Limited (ASX:CF1) Executive Chairman Craig Mason talks about how the company's digital platform provides an electronic centralised framework to manage AFSL-centric (Stockbroker/Financial Planner/Adviser) workflows for compliance, capital raising and operational efficiencies.
Read More21 Apr 2025 - Navigating the FDA Process and Clinical Trial Hurdles
Read More03 Jun 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses measures of growth, inflationary pressures, and similarities between post-war environments and the current economic situation.
Read More29 Nov 2019 - Xplore Wealth Limited (ASX:XPL) CEO, Michael Wright, talks about the benefits of the company's non-aligned platform following the Hayne Royal Commission and key priorities for FY20.
Read More27 Nov 2023 - Enlitic CEO Michael Sistenich discusses the company's AI solutions for healthcare data management as the company gears up for its December IPO.
Read More22 Nov 2022 - Radiopharmaceutical Theranostics Limited (ASX:RAD) Managing Director and CEO Riccardo Canevari discusses the progress of the company's brain, lung and prostate cancer therapies.
Read More
